Lineage Cell, Cancer Research U.K. advance cancer vaccine

By The Science Advisory Board staff writers

October 13, 2020 -- Lineage Cell Therapeutics and partner Cancer Research U.K. have posted positive preliminary phase I results from an ongoing study of VAC2 in non-small cell lung cancer (NSCLC).

In the study, VAC2 potently induced immune responses with high levels of peripheral antigen-specific responses and peripheral antigen-specific immunogenicity in all patients. Based on these results, the company will seek to evaluate VAC2 in combination with other therapies such as chemotherapy and programmed cell death-1 (PD-1) immunotherapy. The vaccine appears to be well-tolerated with no unexpected adverse events.

VAC2 is an allogeneic, off-the-shelf cancer vaccine product candidate designed to stimulate patient immune responses to an antigen commonly expressed in cancerous cells but not in normal adult cells. VAC2 is produced via a pluripotent cell technology platform that uses directed differentiation to nonproliferating mature dendritic cells, the most potent antigen-presenting cells in the body. The VAC technology platform can be modified to carry any antigen, including patient-specific tumor neoantigens or viral antigens.

Recently, Lineage exercised its option to acquire data from Cancer Research U.K. and assumed responsibility for further development and future opportunities derived from the VAC platform. Cancer Research U.K.'s Centre for Drug Development will conclude the ongoing clinical trial.

NCI, Cancer Research U.K. fund project to spur cancer research
The U.S. National Cancer Institute (NCI) has partnered with Cancer Research U.K. to fund Cancer Grand Challenges, an international initiative to support...
Cancer Research UK, Abcam partner on cancer antibodies
Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used...

Copyright © 2020

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter